Your browser is no longer supported. Please, upgrade your browser.
Settings
GHDX Genomic Health, Inc. daily Stock Chart
GHDX [NASD]
Genomic Health, Inc.
Index- P/E109.02 EPS (ttm)0.68 Insider Own0.70% Shs Outstand37.90M Perf Week-0.41%
Market Cap2.83B Forward P/E44.31 EPS next Y1.68 Insider Trans-94.16% Shs Float35.88M Perf Month-10.52%
Income26.30M PEG6.34 EPS next Q0.28 Inst Own90.90% Short Float3.86% Perf Quarter7.54%
Sales394.10M P/S7.17 EPS this Y725.80% Inst Trans2.08% Short Ratio3.52 Perf Half Y14.63%
Book/sh7.46 P/B10.00 EPS next Y14.80% ROA9.00% Target Price79.86 Perf Year125.49%
Cash/sh5.53 P/C13.48 EPS next 5Y17.20% ROE10.90% 52W Range30.04 - 92.18 Perf YTD15.77%
Dividend- P/FCF42.50 EPS past 5Y29.70% ROI8.60% 52W High-19.10% Beta0.97
Dividend %- Quick Ratio4.60 Sales past 5Y8.50% Gross Margin83.70% 52W Low148.24% ATR2.60
Employees863 Current Ratio4.60 Sales Q/Q19.50% Oper. Margin6.10% RSI (14)46.16 Volatility2.63% 3.97%
OptionableYes Debt/Eq0.00 EPS Q/Q351.40% Profit Margin6.50% Rel Volume1.61 Prev Close74.23
ShortableYes LT Debt/Eq0.00 EarningsFeb 20 AMC Payout0.00% Avg Volume394.00K Price74.57
Recom2.80 SMA20-2.95% SMA50-0.71% SMA20014.12% Volume634,375 Change0.46%
Feb-21-19Reiterated Needham Strong Buy $86 → $97
Jan-03-19Initiated Needham Strong Buy $86
Dec-19-18Initiated Oppenheimer Perform
Oct-23-18Resumed Raymond James Mkt Perform
Jun-13-18Downgrade Ladenburg Thalmann Buy → Neutral
Dec-20-17Downgrade William Blair Outperform → Mkt Perform
Dec-13-17Downgrade JP Morgan Neutral → Underweight
May-03-17Downgrade Raymond James Outperform → Mkt Perform
Jan-18-17Initiated Deutsche Bank Hold $31
Feb-11-16Reiterated Canaccord Genuity Buy $44 → $38
Jan-11-16Downgrade Piper Jaffray Overweight → Neutral
Jan-07-16Reiterated Barclays Underweight $25 → $27
Jan-06-16Upgrade Canaccord Genuity Hold → Buy $26 → $44
Nov-23-15Upgrade UBS Neutral → Buy $29 → $38
Nov-04-15Upgrade Raymond James Mkt Perform → Outperform
Sep-02-15Initiated Barclays Underweight $25
Aug-28-15Upgrade Raymond James Underperform → Mkt Perform
Aug-05-15Reiterated Canaccord Genuity Hold $28 → $26
Mar-10-15Initiated UBS Neutral $34
Aug-11-14Reiterated Canaccord Genuity Hold $30 → $27
Mar-08-19 10:10AM  Geron's (GERN) Q4 Loss In Line, Revenues Beat, Stock Up Zacks
Mar-01-19 09:39AM  Esperion (ESPR) Reports Wider-Than-Expected Loss in Q4 Zacks
09:33AM  Spectrum (SPPI) Misses Earnings Estimates in Q4, Tops Sales Zacks
Feb-28-19 10:54AM  Sarepta (SRPT) Q4 Earnings Lag Estimates, Exondys 51 Sales Up Zacks
01:02AM  Biocartis Group NV: BIOCARTIS ANNOUNCES 2018 RESULTS AND 2019 OUTLOOK GlobeNewswire
Feb-27-19 08:25AM  Arena Pharmaceuticals (ARNA) Beats on Q4 Earnings & Revenues Zacks
Feb-25-19 07:54PM  Invitae: Buy at the High? Motley Fool
Feb-22-19 10:20AM  Earnings Estimates Rising for Genomic Health (GHDX): Will It Gain? Zacks
08:11AM  Edited Transcript of GHDX earnings conference call or presentation 20-Feb-19 9:30pm GMT Thomson Reuters StreetEvents
Feb-21-19 04:54PM  How The 'Earnings Risk' Led This Highly Rated Medical Stock Into A Deluge Investor's Business Daily -6.35%
03:39PM  Genomic Health Continues Its Profitable Ways Motley Fool
09:25AM  Genomic Health (GHDX) Q4 Earnings Beat Estimates, Margins Up Zacks
07:32AM  The Daily Biotech Pulse: Genomic Health Earnings, AbbVie's Humira Approved For Another Indication In Japan Benzinga
07:31AM  Dow Jones Futures: Top Stock Signals Breakout On Earnings; Nike Ripped Investor's Business Daily
Feb-20-19 11:20PM  Genomic Health, Inc. (GHDX) Q4 2018 Earnings Conference Call Transcript Motley Fool
06:15PM  Genomic Health (GHDX) Beats Q4 Earnings and Revenue Estimates Zacks
05:31PM  Genomic Health: 4Q Earnings Snapshot Associated Press
04:05PM  Genomic Health Reports Record 2018 Fourth Quarter and Year-end Financial Results and Provides 2019 Financial Guidance PR Newswire
07:34AM  The Daily Biotech Pulse: Teva Settles With FTC, Setback For Merck In Liver Cancer Trial, Sienna Biopharma Offering Benzinga
Feb-18-19 08:04AM  What's in the Cards for Genomic Health (GHDX) in Q4 Earnings? Zacks
Feb-14-19 10:38AM  Biotech Hedge Fund Bailed on Drugmaker Before Its Depression Treatment Scored Bloomberg
Feb-13-19 08:00AM  Genomic Health to Announce Fourth Quarter and Year-End 2018 Financial Results and Host Conference Call on Wednesday, February 20, 2019 PR Newswire
Feb-08-19 10:33PM  Here's Why Genetic Testing Stocks Rose as Much as 31.8% in January Motley Fool
Feb-05-19 08:00AM  Oncotype DX® Genomic Prostate Score® Established as First Genomic Test with Prospective Validation for Predicting Adverse Pathology in Newly Diagnosed Patients PR Newswire
Jan-22-19 07:11PM  3 Top Growth Stocks to Buy Right Now Motley Fool
Jan-18-19 12:58PM  Does Genomic Health, Inc.s (NASDAQ:GHDX) CEO Salary Compare Well With Others? Simply Wall St.
05:00AM  Top Picks 2019- Genomic Health GHDX MoneyShow
Jan-14-19 09:30AM  Is Genomic Health (GHDX) Stock Outpacing Its Medical Peers This Year? Zacks
Jan-08-19 07:30AM  Investor Expectations to Drive Momentum within National Beverage, Rexford Industrial Realty, OUTFRONT Media, Genomic Health, Zumiez, and Timken Steel Discovering Underlying Factors of Influence GlobeNewswire
Jan-07-19 10:09AM  Emergent (EBS) CEO Abdun Nabi to Retire, Kramer to Succeed Zacks
08:00AM  Genomic Health Marks More than 1 Million Patients Worldwide Who Have Benefited from Oncotype DX Testing in Personalizing Cancer Treatment Decisions to Improve Outcomes PR Newswire
Jan-04-19 06:13PM  Biogen Begins Improved Dosing Regimen on Tysabri in Phase III Zacks +5.94%
10:01AM  Vertex Joins Forces With Arbor to Build Gene-Editing Therapies Zacks
Dec-27-18 12:27PM  3 Gene Therapy Stocks to Play Biotechs Future InvestorPlace
09:30AM  Is Genomic Health (GHDX) Outperforming Other Medical Stocks This Year? Zacks
08:37AM  Alnylam (ALNY) Surges: Stock Moves 8.7% Higher Zacks
Dec-26-18 07:57AM  Here's Why You Should Invest in Genomic Health (GHDX) Now Zacks +6.74%
07:57AM  Here's Why You Should Buy Integer Holdings (ITGR) Stock Now Zacks
Dec-21-18 01:36PM  6 Genome Sequencing Stocks to Buy for Big Health-Care Profits Kiplinger
Dec-19-18 08:00AM  NICE Expands Recommendation for the Oncotype DX Breast Recurrence Score® Test to More Patients with Early-Stage Breast Cancer Within the United Kingdom PR Newswire
Dec-18-18 05:32PM  Achillion Reports Positive Interim Data on Factor D Inhibitors Zacks
08:00AM  Genomic Health to Present at the 37th Annual J.P. Morgan Healthcare Conference PR Newswire
Dec-17-18 11:26PM  Should You Buy Genomic Health, Inc. (GHDX)? Insider Monkey
Dec-12-18 08:25AM  5 Stocks That Popped More Than 100% in 2018 Defying All Odds Zacks
Dec-10-18 09:30AM  Is Genomic Health (GHDX) Stock Outpacing Its Medical Peers This Year? Zacks
08:00AM  Multiple Oncotype DX Study Presentations at the 2018 San Antonio Breast Cancer Symposium Reinforce Real-world Value of the Oncotype DX Breast Recurrence Score® Test in Patients Regardless of Age or Race PR Newswire
Dec-06-18 10:31AM  Patterson Companies (PDCO) Q2 Earnings Beat, Revenues Miss Zacks
09:30AM  Genomic Health (GHDX) Down 18% Since Last Earnings Report: Can It Rebound? Zacks
Dec-05-18 09:34AM  HealthEquity (HQY) Earnings & Revenues Beat Estimates in Q3 Zacks
Dec-04-18 09:46AM  Genomic Health (GHDX), BioCartis Extend Deal to Urology Zacks -5.17%
Dec-03-18 04:51PM  Genomic Health and Biocartis Expand Collaboration to Urology with the Development of an Idylla Oncotype DX® Genomic Prostate Score® Test PR Newswire
07:27AM  What Type Of Shareholder Owns Genomic Health Incs (NASDAQ:GHDX)? Simply Wall St.
Nov-29-18 08:45AM  Veeva Systems (VEEV) Q3 Earnings & Revenues Beat Estimates Zacks
08:00AM  New Analysis of NSABP Randomized B-20 Study Confirms Patients with Oncotype DX Breast Recurrence Score® Results Greater Than 25 Have Life-saving Substantial Benefit from Chemotherapy, Reinforcing the Conclusions of the Landmark TAILORx Study PR Newswire
06:31AM  5 Stocks to Gain as Fed Chair "Blinks" on Rates Zacks
Nov-28-18 07:20AM  Market Trends Toward New Normal in Genomic Health, Beacon Roofing Supply, Cronos Group, Aimmune Therapeutics, OGE Energy, and Spartan Motors Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Nov-20-18 02:37PM  Medtronic (MDT) Tops Q2 Earnings on Strong Segmental Growth Zacks
Nov-19-18 04:13PM  3 High-Growth Stocks That Are Just Getting Started Motley Fool
08:00AM  Genomic Health Announces Presentation of Two Large Studies at the 2018 San Antonio Breast Cancer Symposium, Reinforcing Real-world Value of the Oncotype DX Breast Recurrence Score® Test PR Newswire
Nov-16-18 04:54PM  This High-Growth Biotech Industry Is as Competitive as Ever Heading Into 2019 Motley Fool
Nov-14-18 08:56AM  Genomic Health Starts Sprinting Motley Fool
Nov-12-18 11:51AM  3 DNA Stocks That Are on the Uptrend InvestorPlace
Nov-09-18 10:20AM  Earnings Estimates Rising for Genomic Health (GHDX): Will It Gain? Zacks
08:21AM  Genomic Health (GHDX) Q3 Earnings and Revenues Top Estimates Zacks
Nov-08-18 08:10AM  The Daily Biotech Pulse: Nantkwest Reports Positive Cancer Vaccine Trial Results, Sarepta Offering Benzinga -7.10%
08:00AM  Genomic Health to Present at the 2018 Canaccord Genuity Medical Technologies & Diagnostics Forum PR Newswire
Nov-07-18 12:48PM  Here's Why Genomic Health Popped as Much as 30.2% Today Motley Fool +27.39%
07:50AM  The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Momenta Strikes Patent License Deal With AbbVie Benzinga
07:09AM  Dow Jones Futures Jump On Election Results; 7 Big Movers On Earnings Investor's Business Daily
Nov-06-18 07:10PM  Genomic Health Inc (GHDX) Q3 2018 Earnings Conference Call Transcript Motley Fool
07:05PM  Genomic Health (GHDX) Surpasses Q3 Earnings and Revenue Estimates Zacks
05:59PM  Genomic Health: 3Q Earnings Snapshot Associated Press
05:04PM  This Highly Rated Medtech Just Crushed Quarterly Expectations Investor's Business Daily
04:05PM  Genomic Health Announces Record Revenue and Profit in Third Quarter 2018 Financial Results; Raises Full Year Guidance PR Newswire
Oct-30-18 04:19PM  IBD Stock Of The Day Aims For Third Quarter Of Double-Digit Growth Investor's Business Daily
08:00AM  Genomic Health to Announce Third Quarter 2018 Financial Results and Host Conference Call on Tuesday, November 6, 2018 PR Newswire
Oct-29-18 08:00AM  Medicare Establishes Final Local Coverage Determination (LCD) for Use of the Oncotype DX® AR-V7 Nucleus Detect Test in Patients with Metastatic Castrate Resistant Prostate Cancer Effective December 10 PR Newswire
Oct-22-18 08:00AM  Genomic Health Announces Multiple Studies Reinforcing Value of Oncotype DX® Tests in Guiding Treatment for Breast and Prostate Cancer Patients PR Newswire
Oct-18-18 08:15AM  New Research Coverage Highlights Altair Engineering, Genomic Health, Seres Therapeutics, REV Group, MACOM Technology Solutions, and New Mountain Finance Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Oct-16-18 10:54AM  Here's Why You Should Invest in GNC Holdings (GNC) Right Now Zacks +5.59%
Oct-11-18 02:02PM  How Did Genomic Health Incs (NASDAQ:GHDX) 1.9% ROE Fare Against The Industry? Simply Wall St.
09:50AM  Molecular Diagnostic Market Gains Momentum: 3 Stocks in Focus Zacks
07:27AM  Here's Why Genomic Health, Inc. Gained 14.8% in September Motley Fool
Oct-10-18 09:54AM  Genomic Health's Test Gets Favored by New NCCN Guidelines Zacks
Oct-09-18 04:15PM  New NCCN Breast Cancer Guidelines Elevate Oncotype DX Breast Recurrence Score® as the Only Preferred Multi-gene Test to Predict Chemotherapy Treatment PR Newswire
09:08AM  Here's Why You Should Invest in Genomic Health (GHDX) Now Zacks
Oct-04-18 10:24AM  Genomic Health's New Data on Oncotype DX GPS to Boost Uptake Zacks
Sep-28-18 08:00AM  New Published Data and Recent Positive Private Payor Coverage Decisions Underscore Value and Utility of the Oncotype DX Genomic Prostate Score® (GPS) Test PR Newswire
Sep-12-18 08:48AM  Genomic Health (GHDX) Hits a 52-Week High: What's Driving It? Zacks
08:00AM  Epic Sciences Announces Completion of $52 Million Series E Financing PR Newswire
05:00AM  [$$] Epic Sciences Gets $52 Million for Cancer Blood Tests The Wall Street Journal
Sep-07-18 08:00AM  German Health Technology Assessment Body (IQWiG) Concludes Only Oncotype DX® has Sufficient Evidence to Guide Breast Cancer Adjuvant Chemotherapy Decisions Based on Landmark TAILORx Study Results PR Newswire
Sep-06-18 08:44AM  Genomic Health Prostate Cancer Business Solid, Cost Woes Stay Zacks
01:02AM  Biocartis Group NV: BIOCARTIS ANNOUNCES H1 2018 RESULTS GlobeNewswire
Aug-29-18 09:59AM  Here's Why You Should Invest in Genomic Health (GHDX) Now Zacks
Aug-24-18 08:25AM  Report: Exploring Fundamental Drivers Behind HomeStreet, Schnitzer Steel Industries, OraSure Technologies, Genomic Health, Benchmark Electronics, and Stoneridge New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Aug-13-18 01:39AM  Edited Transcript of GHDX earnings conference call or presentation 2-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
Aug-08-18 04:23PM  Genomic Health Starts Its Marathon Motley Fool
Aug-03-18 10:16AM  Genomic Health (GHDX) Q2 Earnings and Revenues Top Estimates Zacks
07:52AM  The Daily Biotech Pulse: Zafgen Executive Departs; Adamas, Acceleron Accelerate On Earnings Benzinga
Genomic Health, Inc., a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions. It offers the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the breast cancer recurrence and chemotherapy benefit. The company also provides the Oncotype DX colon cancer test, which is used to predict the likelihood of colon cancer recurrence in patients with stage II disease, as well as for use in patients with stage III disease treated with oxaliplatin-containing adjuvant therapy; Oncotype DX prostate cancer test, which provides a genomic prostate score to predict disease aggressiveness in men with low risk prostate cancer, as well as to enhance treatment decisions for prostate cancer patients in conjunction with the Gleason score; and Oncotype DX AR-V7 nucleus detect tests for men with metastatic castration-resistant prostate cancer. In addition, it develops Oncoytpe DXi IVD breast recurrence score test; and Oncotype DX GPS test. The company offers its products through a network of distributors. Genomic Health, Inc. has license and development agreement with Biocartis N.V. to develop and commercialize an in vitro diagnostic of the Oncotype DX breast cancer test; collaboration agreement with Epic Sciences, Inc. to commercializeAR-V7 Nucleus Detect test; and license and development agreement with Cleveland Diagnostics, Inc. to develop and commercialize new prostate cancer tests. The company was founded in 2000 and is based in Redwood City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Pla FredericCOOMar 19Option Exercise28.774,700135,23436,275Mar 19 06:42 PM
BAKER BROS. ADVISORS LPDirectorMar 19Sale74.3450,1003,724,59450,553Mar 19 05:48 PM
BAKER BROS. ADVISORS LPDirectorMar 19Sale74.3450,1003,724,59450,553Mar 19 05:37 PM
BAKER BROS. ADVISORS LPDirectorMar 19Sale74.63105,1267,845,64850,601Mar 19 05:31 PM
Pla FredericCOOMar 19Sale75.004,700352,50031,575Mar 19 06:42 PM
Pla FredericCOOMar 18Option Exercise27.481,00027,48032,575Mar 19 06:42 PM
Pla FredericCOOMar 18Sale75.121,00075,12231,575Mar 19 06:42 PM
BAKER BROS. ADVISORS LPDirectorMar 18Sale74.19109,5338,125,96850,702Mar 19 05:31 PM
BAKER BROS. ADVISORS LPDirectorMar 15Sale74.6455,3474,131,08850,808Mar 19 05:31 PM
BAKER BROS. ADVISORS LPDirectorMar 14Sale76.4965,0944,978,78750,861Mar 14 05:03 PM
BAKER BROS. ADVISORS LPDirectorMar 13Sale75.9280,2536,092,92350,924Mar 14 05:03 PM
Cole G BradleyCFOMar 12Option Exercise21.0515,000315,70058,722Mar 14 04:06 PM
BAKER BROS. ADVISORS LPDirectorMar 12Sale75.6374,1805,610,24851,001Mar 14 05:03 PM
Cole G BradleyCFOMar 12Sale75.1515,0001,127,27343,722Mar 14 04:06 PM
BAKER BROS. ADVISORS LPDirectorMar 11Sale75.0049,0353,677,48451,072Mar 11 04:59 PM
Popovits Kimberly JPresident and CEOMar 08Sale73.2210,000732,237125,952Mar 12 09:47 PM
BAKER BROS. ADVISORS LPDirectorMar 08Sale73.5522,7001,669,51951,119Mar 11 04:59 PM
Vaughn James JChief Commercial OfficerMar 07Option Exercise31.123,00093,36025,790Mar 11 06:42 PM
BAKER BROS. ADVISORS LPDirectorMar 07Sale73.722,000147,44551,141Mar 11 04:59 PM
Vaughn James JChief Commercial OfficerMar 07Sale73.873,000221,59622,790Mar 11 06:42 PM
BAKER BROS. ADVISORS LPDirectorMar 05Sale77.0410,300793,50451,143Mar 05 06:30 PM
Shak StevenChief Scientific OfficerMar 04Option Exercise28.057,500210,375342,979Mar 05 04:17 PM
Shak StevenChief Scientific OfficerMar 04Sale75.897,500569,202335,479Mar 05 04:17 PM
BAKER BROS. ADVISORS LPDirectorMar 04Sale76.4927,8112,127,24951,153Mar 05 06:30 PM
Shak StevenChief Scientific OfficerMar 01Option Exercise28.0525,000701,250360,479Mar 05 04:17 PM
Shak StevenChief Scientific OfficerMar 01Sale77.2225,0001,930,424335,479Mar 05 04:17 PM
BAKER BROS. ADVISORS LPDirectorMar 01Sale77.2079,2766,120,38751,180Mar 05 06:30 PM
Shak StevenChief Scientific OfficerFeb 28Option Exercise19.3525,000483,850360,479Mar 01 07:05 PM
BAKER BROS. ADVISORS LPDirectorFeb 28Sale76.2060045,71951,256Feb 28 06:22 PM
Shak StevenChief Scientific OfficerFeb 28Sale76.4025,0001,909,972335,479Mar 01 07:05 PM
Shak StevenChief Scientific OfficerFeb 27Option Exercise17.1825,000429,500360,479Mar 01 07:05 PM
Shak StevenChief Scientific OfficerFeb 27Sale76.5925,0001,914,824335,479Mar 01 07:05 PM
BAKER BROS. ADVISORS LPDirectorFeb 27Sale76.6539,1092,997,79251,257Feb 28 06:21 PM
BAKER BROS. ADVISORS LPDirectorFeb 26Option Exercise17.5916,500290,2359,100,815Feb 28 06:21 PM
BAKER BROS. ADVISORS LPDirectorFeb 26Sale78.118,650675,61451,295Feb 28 06:21 PM
FUCHS HENRY JDirectorFeb 25Option Exercise27.753,52197,7089,853Feb 26 04:51 PM
FUCHS HENRY JDirectorFeb 25Sale79.023,521278,2266,332Feb 26 04:51 PM
Cohen Fred EDirectorFeb 22Option Exercise26.0110,000260,10077,619Feb 26 04:49 PM
FUCHS HENRY JDirectorFeb 22Option Exercise32.2226,479853,19232,811Feb 26 04:51 PM
Cohen Fred EDirectorFeb 22Sale78.8610,000788,55967,619Feb 26 04:49 PM
FUCHS HENRY JDirectorFeb 22Sale81.8926,4792,168,4036,332Feb 26 04:51 PM
Leber LauraChief Communication OfficerFeb 21Option Exercise22.981,81741,75522,666Feb 22 08:45 PM
Pla FredericCOOFeb 21Sale86.5178367,73631,575Feb 25 08:19 PM
Leber LauraChief Communication OfficerFeb 21Sale80.245,634452,07617,032Feb 22 08:45 PM
Leber LauraChief Communication OfficerFeb 20Option Exercise17.1818,750322,12539,599Feb 22 08:45 PM
Leber LauraChief Communication OfficerFeb 20Sale82.8718,7501,553,82420,849Feb 22 08:45 PM
Pla FredericCOOFeb 19Option Exercise28.555,700162,71445,378Feb 21 07:24 PM
Vaughn James JChief Commercial OfficerFeb 19Option Exercise30.231,19536,13025,320Feb 21 07:24 PM
Pla FredericCOOFeb 19Sale83.169,700806,66135,678Feb 21 07:24 PM
Radford Jason W.Chief Legal OfficerFeb 19Sale83.163,508291,70934,888Feb 21 07:25 PM
Popovits Kimberly JPresident and CEOFeb 14Option Exercise17.1847,900822,922164,882Feb 19 07:38 PM
Popovits Kimberly JPresident and CEOFeb 14Sale81.7047,9003,913,615116,982Feb 19 07:38 PM
Cole G BradleyCFOFeb 12Option Exercise21.0515,000315,70058,067Feb 14 05:50 PM
Cole G BradleyCFOFeb 12Sale80.8715,0001,213,02448,067Feb 14 05:50 PM
Vaughn James JChief Commercial OfficerFeb 07Option Exercise31.123,00093,36027,125Feb 11 07:53 PM
Vaughn James JChief Commercial OfficerFeb 07Sale77.423,000232,27224,125Feb 11 07:53 PM
Shak StevenChief Scientific OfficerFeb 04Option Exercise20.6625,000516,500364,671Feb 05 05:55 PM
Shak StevenChief Scientific OfficerFeb 04Sale76.7325,0001,918,308339,671Feb 05 05:55 PM
Shak StevenChief Scientific OfficerFeb 01Option Exercise22.9825,000574,500364,671Feb 05 05:55 PM
Shak StevenChief Scientific OfficerFeb 01Sale75.8625,0001,896,384339,671Feb 05 05:55 PM
Shak StevenChief Scientific OfficerJan 31Option Exercise29.3425,000733,500364,671Feb 01 07:08 PM
Shak StevenChief Scientific OfficerJan 31Sale74.9825,0001,874,571339,671Feb 01 07:08 PM
Shak StevenChief Scientific OfficerJan 30Option Exercise29.3425,000733,500364,671Feb 01 07:08 PM
Shak StevenChief Scientific OfficerJan 30Sale73.4925,0001,837,229339,671Feb 01 07:08 PM
BAKER BROS. ADVISORS LPDirectorJan 28Sale71.0746,4773,302,98051,304Jan 30 04:00 PM
BAKER BROS. ADVISORS LPDirectorJan 25Sale72.2091,9166,636,64851,349Jan 25 05:19 PM
BAKER BROS. ADVISORS LPDirectorJan 24Sale72.0279,4035,718,58851,438Jan 25 05:19 PM
BAKER BROS. ADVISORS LPDirectorJan 23Sale70.6737,5122,651,09251,514Jan 25 05:19 PM
BAKER BROS. ADVISORS LPDirectorJan 22Sale71.0051,6063,664,03151,550Jan 22 05:27 PM
BAKER BROS. ADVISORS LPDirectorJan 22Sale71.6112,800916,64151,600Jan 22 05:26 PM
Radford Jason W.Chief Legal OfficerJan 22Sale71.442,963211,68331,326Jan 24 06:30 PM
BAKER BROS. ADVISORS LPDirectorJan 18Sale72.73177,14212,884,34551,612Jan 22 05:26 PM
Vaughn James JChief Commercial OfficerJan 17Option Exercise28.742,22263,85419,985Jan 22 07:33 PM
BAKER BROS. ADVISORS LPDirectorJan 17Sale70.79181,74712,866,12551,783Jan 22 05:26 PM
BAKER BROS. ADVISORS LPDirectorJan 14Sale70.0760042,04351,958Jan 14 05:11 PM
BAKER BROS. ADVISORS LPDirectorJan 11Sale70.2228,4741,999,53351,959Jan 14 05:11 PM
BAKER BROS. ADVISORS LPDirectorJan 10Sale70.2810,185715,78051,986Jan 14 05:11 PM
Vaughn James JChief Commercial OfficerJan 08Option Exercise31.123,00093,36020,763Jan 09 07:42 PM
Cole G BradleyCFOJan 08Option Exercise21.0515,000315,70054,047Jan 09 07:43 PM
Cole G BradleyCFOJan 08Sale67.0315,0001,005,40144,047Jan 09 07:43 PM
Vaughn James JChief Commercial OfficerJan 08Sale67.063,000201,18117,763Jan 09 07:42 PM
Popovits Kimberly JPresident and CEODec 18Sale66.6925,0001,667,285116,982Dec 19 05:59 PM
Popovits Kimberly JPresident and CEODec 17Sale66.8925,0001,672,242141,982Dec 19 05:59 PM
BAKER BROS. ADVISORS LPDirectorDec 12Sale73.0918,5001,352,08751,686Dec 12 05:57 PM
Cole G BradleyCFODec 11Option Exercise21.0515,000315,70059,047Dec 13 06:24 PM
GRAHAM GINGER LDirectorDec 11Option Exercise19.2524,750476,43851,648Dec 13 06:25 PM
Cole G BradleyCFODec 11Sale71.9515,0001,079,21944,047Dec 13 06:24 PM
BAKER BROS. ADVISORS LPDirectorDec 11Sale74.0757,5544,262,82351,704Dec 12 05:57 PM
BAKER BROS. ADVISORS LPDirectorDec 10Sale73.839,366691,48351,760Dec 12 05:57 PM
BAKER BROS. ADVISORS LPDirectorDec 07Sale76.15102,4557,802,35851,769Dec 07 05:16 PM
Vaughn James JChief Commercial OfficerDec 06Option Exercise31.123,00093,36020,763Dec 07 05:03 PM
Vaughn James JChief Commercial OfficerDec 06Sale75.303,000225,88817,763Dec 07 05:03 PM
BAKER BROS. ADVISORS LPDirectorDec 06Sale75.4692,6796,993,62251,868Dec 07 05:16 PM
BAKER BROS. ADVISORS LPDirectorDec 04Sale75.6232,7762,478,44751,957Dec 07 05:15 PM
Shak StevenChief Scientific OfficerDec 03Option Exercise17.331,50025,995338,241Dec 06 07:47 PM
BAKER BROS. ADVISORS LPDirectorDec 03Sale78.49202,13415,865,83351,988Dec 03 05:40 PM
Shak StevenChief Scientific OfficerDec 03Sale78.181,500117,273336,741Dec 06 07:47 PM
BAKER BROS. ADVISORS LPDirectorNov 30Sale79.20204,75716,217,02252,183Dec 03 05:39 PM
BAKER BROS. ADVISORS LPDirectorNov 29Sale77.9551,2783,997,19152,380Dec 03 05:39 PM
BAKER BROS. ADVISORS LPDirectorNov 28Sale75.61250,39218,932,28352,429Nov 28 05:44 PM